Get the Stockscreener App
3.52
3.30%
-0.12
After Hours:
3.50
-0.02
-0.57%
Incannex Healthcare Inc stock is traded at $3.52, with a volume of 120.05K.
It is down -3.30% in the last 24 hours and down -13.94% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$3.64
Open:
$3.64
24h Volume:
120.05K
Relative Volume:
0.23
Market Cap:
$42.12M
Revenue:
$12,000
Net Income/Loss:
$-48.50M
P/E Ratio:
-0.2062
EPS:
-17.0687
Net Cash Flow:
$-19.78M
1W Performance:
-11.11%
1M Performance:
-13.94%
6M Performance:
-62.69%
1Y Performance:
-41.91%
1-Day Range:
$3.51
$3.71
1-Week Range:
$3.51
$4.00
52-Week Range:
$2.49
$49.80
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
3.52 | 43.55M | 12,000 | -48.50M | -19.78M | -17.07 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc Stock (IXHL) Latest News
Incannex reactivates share repurchase program, cites ‘significant disconnect’ between its market cap and financial strength - MSN
IXHL Technical Analysis | Trend, Signals & Chart Patterns | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill
Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA - Sleep Review
Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary - TradingView
IXHL: Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases - TradingView
Incannex Healthcare (NASDAQ: IXHL) grows cash to $74.5M amid $16.8M loss - Stock Titan
Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea - TradingView
Incannex launches DReAMzz study for sleep apnea treatment - Investing.com UK
Incannex Healthcare Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea, Advancing Late-Stage Development 1 - Minichart
Incannex launches DReAMzz study for sleep apnea treatment By Investing.com - Investing.com South Africa
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea - The Manila Times
Incannex Healthcare Inc. Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Treatment - Quiver Quantitative
New sleep apnea drug enters dose-test in Incannex DReAMzz trial - Stock Titan
Incannex Launches DReAMzz Study for IHL-42X Sleep Apnea - TipRanks
Incannex Healthcare commences DReAMzz study for IHL-42X, 14 sites onboarded - TradingView
Incannex (IXHL) launches DReAMzz dose-optimization study of IHL-42X for sleep apnea - Stock Titan
IXHL Q3'26 Earnings: EPS estimate is (0.60) USD - TradingView
Incannex Wins MedTech Award for IHL-42X Sleep Therapy - TipRanks
Incannex Healthcare Wins MedTech Breakthrough Award for Innovative Obstructive Sleep Apnea Drug IHL-42X - Minichart
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development - The Manila Times
New oral sleep apnea drug IHL-42X wins global MedTech prize - Stock Titan
Incannex Healthcare wins MedTech Breakthrough award for IHL-42X after positive Phase 2 data - TradingView
Incannex (NASDAQ: IXHL) earns MedTech Breakthrough award for IHL-42X sleep apnea therapy - Stock Titan
TradingKey - TradingKey
Incannex Cannabis Gains Attention Across ASX 200 Healthcare Sector - Kalkine Media
Number of shareholders of Incannex Healthcare Inc. – NASDAQ:IXHL - TradingView
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough - The Manila Times
Incannex Healthcare (IXHL) Expected to Announce Earnings on Thursday - MarketBeat
Incannex Healthcare wins award for innovative drug IHL-42X treating obstructive sleep apnea. - Pluang
Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.8%Here's Why - MarketBeat
IXHL SEC FilingsIncannex Healthcare Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
2026's 10 Worst-Performing Stocks | Investing - U.S. News Money
Incannex says it holds $75 million in cash with zero debt after financing - MSN
$Incannex Healthcare (IXHL.US)$ - Moomoo
What Puts ASX 200 Incannex Cannabis Stocks in Focus? - Kalkine Media
IXHL Should I Buy - Intellectia AI
Incannex supports White House order on mental health treatments By Investing.com - Investing.com India
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):